7-(benzyloxy)-N-(2-chloro-5-methoxyphenyl)-5-isopropoxyquinazolin-4-amine | 379230-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(benzyloxy)-N-(2-chloro-5-methoxyphenyl)-5-isopropoxyquinazolin-4-amine
• 英文别名: 7-Benzyloxy-4-(2-chloro-5-methoxyanilino)-5-isopropoxyquinazoline；N-(2-chloro-5-methoxyphenyl)-7-phenylmethoxy-5-propan-2-yloxyquinazolin-4-amine
• CAS: 379230-01-0
• 化学式: C₂₅H₂₄ClN₃O₃
• 分子量: 449.937
• InChiKey: ZBTRJLYOTIKIIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  7-(benzyloxy)-N-(2-chloro-5-methoxyphenyl)-5-isopropoxyquinazolin-4-amine 在 三氟乙酸 作用下， 以66%的产率得到4-[(2-chloro-5-methoxyphenyl)amino]-5-isopropoxyquinazolin-7-ol
  参考文献：
  名称：

  N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

  摘要：

  Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines that display high affinity and specificity for the tyrosine kinase domain of the c-Src and Abl enzymes. These compounds exhibit high selectivity for SFKs over a panel of recombinant protein kinases, excellent pharmacokinetics, and in vivo activity following oral dosing. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases. AZD0530 displays excellent pharmacokinetic parameters in animal preclinically and in man (t(1/2) = 40 h). AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. AZD0530 is currently undergoing clinical evaluation in man.

  DOI：

  10.1021/jm060434q
• 作为产物：
  描述：

  3,5-Dibenzyloxyaniline hydrochloride 在 吡啶 、 sodium hydroxide 、 双氧水 、 吡啶盐酸盐 、 N,N-二异丙基乙胺 、 三苯基膦 、 三氯氧磷 作用下， 以 乙醇 、 二氯甲烷 、 乙二醇甲醚 、 水 、 1,2-二氯乙烷 、 异丙醇 为溶剂， 反应 14.5h， 生成 7-(benzyloxy)-N-(2-chloro-5-methoxyphenyl)-5-isopropoxyquinazolin-4-amine
  参考文献：
  名称：

  N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

  摘要：

  Src family kinases (SFKs) are nonreceptor tyrosine kinases that are reported to be critical for cancer progression. We report here a novel subseries of C-5-substituted anilinoquinazolines that display high affinity and specificity for the tyrosine kinase domain of the c-Src and Abl enzymes. These compounds exhibit high selectivity for SFKs over a panel of recombinant protein kinases, excellent pharmacokinetics, and in vivo activity following oral dosing. N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) inhibits c-Src and Abl enzymes at low nanomolar concentrations and is highly selective over a range of kinases. AZD0530 displays excellent pharmacokinetic parameters in animal preclinically and in man (t(1/2) = 40 h). AZD0530 is a potent inhibitor of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo and led to a significant increase in survival in a highly aggressive, orthotopic model of human pancreatic cancer when dosed orally once daily. AZD0530 is currently undergoing clinical evaluation in man.

  DOI：

  10.1021/jm060434q

文献信息

• [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES<br/>[FR] DERIVES DE QUINAZOLINE DESTINES AU TRAITEMENT DES MALADIES INDUITES PAR LES LYMPHOCYTES T
  申请人：ASTRAZENECA AB

  公开号：WO2003045395A1

  公开（公告）日：2003-06-05

  The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R1, R2, R3 and Q2 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

  本发明涉及使用式（I）中各自具有定义于本说明书中的任何含义的Q1、Z、m、R1、R2、R3和Q2的喹唑啉衍生物制造用于预防或治疗温血动物的T细胞介导疾病或医疗情况的药物。
• [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS<br/>[FR] DERIVES DE LA QUINAZOLINE POUR LE TRAITEMENT DE TUMEURS
  申请人：ASTRAZENECA AB

  公开号：WO2001094341A1

  公开（公告）日：2001-12-13

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R?1, R2, R3 and Q2¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  本发明涉及公式（I）的喹唑啉衍生物，其中Q1，Z，m，R?1，R2，R3和Q2¿中的每一个都具有描述中定义的任何含义；制备它们的过程，含有它们的制药组合物以及它们在制造用于抗侵袭剂的药物，用于包含和/或治疗实体肿瘤疾病。
• Quinazoline derivatives for treatment of tumours
  申请人：——

  公开号：US20040214841A1

  公开（公告）日：2004-10-28

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 1

  本发明涉及公式（I）的喹嗪衍生物，其中Q1、Z、m、R1、R2、R3和Q2中的每个都具有描述中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于抗侵袭剂以限制和/或治疗实体肿瘤疾病的药物中的使用。
• Quinazoline derivatives for the treatment of t cell mediated diseases
  申请人：Moore Corine Nelly

  公开号：US20050038050A1

  公开（公告）日：2005-02-17

  The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal.

  本发明涉及在温血动物中预防或治疗T细胞介导的疾病或医疗状况的药物制剂的制造中使用公式（I）的喹唑啉衍生物，其中Q1，Z，m，R1，R2，R3和Q2中的每一个都具有描述中定义的任何含义。
• Quinazoline derivatives for the treatment of tumours
  申请人：Hennequin Francois Andre Laurent

  公开号：US20060258642A1

  公开（公告）日：2006-11-16

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  本发明涉及公式（I）的喹唑啉衍生物，其中Q1，Z，m，R1，R2，R3和Q2中的每一个都具有描述中定义的任何含义；其制备过程，含有它们的制药组合物以及它们在制造用于抗侵袭剂在包含和/或治疗实体肿瘤疾病的药物中的应用。